07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Hyperion, Valeant Pharmaceuticals deal

Hyperion completed the acquisition of worldwide rights to Buphenyl sodium phenylbutyrate from Valeant's Ucyclyd Pharma Inc. subsidiary. The exercise price was $19 million. The subsidiary exercised its option to retain Ammonul for $32 million. After...
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

Hyperion, Valeant Pharmaceuticals deal

Hyperion exercised its option under an amended 2007 deal with Valeant's Medicis Pharmaceutical Corp. subsidiary to acquire worldwide rights to Buphenyl sodium phenylbutyrate and Ammonul . Hyperion will pay $22 million up front to Valeant,...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Hyperion, Medicis deal

Hyperion acquired worldwide rights to Ravicti glycerol phenylbutyrate ( HPN-100 ) from Medicis' Ucyclyd Pharma Inc. subsidiary. The companies also amended a 2007 deal to give Hyperion an option to acquire worldwide rights to Buphenyl...
08:00 , Jan 3, 2011 |  BioCentury  |  Emerging Company Profile

Hyperion: Building a better mop

The only drug approved as a chronic treatment for urea cycle disorders requires high doses and has high sodium content, resulting in a risk of hypertension and reduced appetite. Hyperion Therapeutics Inc. believes its sodium-free...
08:00 , Mar 3, 2008 |  BC Week In Review  |  Clinical News

Ammonul: Phase II started

Hyperion began a double-blind, U.S. Phase II trial to compare 2.75 and 5.5 g/m 2 of intravenous Ammonul vs. placebo in hospitalized adults. Ammonul has Orphan Drug designation from FDA to treat grade III and...
01:12 , Oct 5, 2007 |  BC Extra  |  Financial News

Hyperion raises $15 million

Hyperion (South San Francisco, Calif.) raised $15 million in a debt financing from Comerica Bank and Life Sciences Capital. The company has U.S. rights to co-promote Ammonul and Buphenyl sodium phenylbutyrate from Medicis (MRX), two...
07:00 , Sep 17, 2007 |  BioCentury  |  Finance

Ebb & Flow

Investors who have followed Mark Levin's lead have rarely been disappointed. Thus it's no surprise that his new venture fund,...
01:12 , Sep 6, 2007 |  BC Extra  |  Financial News

Hyperion raises $40 million

Hyperion (South San Francisco, Calif.) raised $40 million in a series B round led by Sofinnova Ventures. Highland Capital Partners; New Enterprise Associates (NEA); and WRF Capital also participated. Hyperion plans to use part of...
07:00 , Sep 3, 2007 |  BC Week In Review  |  Company News

Medicis, Hyperion deal

MRX's Ucyclyd Pharma Inc. subsidiary granted Hyperion rights to research and develop GT4P to treat urea cycle disorder (UCD) and hepatic encephalopathy, and Ammonul to treat the latter indication. GT4P, a pro-drug of phenylbutyrate, is...
08:00 , Feb 21, 2005 |  BC Week In Review  |  Clinical News

Ammonul regulatory update

FDA approved Ammonul as an adjunctive therapy to treat acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. The combination of 10% sodium phenylacetate and 10% sodium benzoate has...